| Symbol | ADAG |
|---|---|
| Name | ADAGENE INC. |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4F, BUILDING C14, NO. 218 XINGHU STREET,SUZHOU INDUSTRIAL PARK, SUZHOU, 215123, China |
| Telephone | +86 512 - 8777-3632 |
| Fax | — |
| — | |
| Website | https://www.adagene.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001818838 |
| Description | Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The companys platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the companys immunotherapy pipeline. Additional info from NASDAQ: |
2026-08-20 19:12
New Form 144/A - Adagene Inc. <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001104659-26-099289 <b>Size:</b> 10 KB
Read more
2026-08-19 14:22
📋 GU CHUNFANG (Officer) plans to sell 40K shares of Adagene Inc. (at $3.95 each, total $158K) Filed: Aug 19, 2026 | ID: 000001
Read more
2026-08-18 22:11
Director DO CUONG V 🟢 acquired 2.0K shares of Adagene Inc. (ADAG) at $3.75 Transaction Date: Aug 14, 2026 | Filing ID: 098426
Read more
2026-08-18 00:32
Director Zhu Li 🟢 acquired 20.0K shares (1 derivative) of Adagene Inc. (ADAG) at $3.00 Transaction Date: Aug 13, 2026 | Filing ID: 097996
Read more
2026-08-18 00:30
Director Cheung Andy Yiu Leung 🟢 acquired 20.0K shares (1 derivative) of Adagene Inc. (ADAG) at $3.00 Transaction Date: Aug 13, 2026 | Filing ID: 097995
Read more
2026-08-18 00:30
Director DO CUONG V 🟢 acquired 20.0K shares (1 derivative) of Adagene Inc. (ADAG) at $3.00 Transaction Date: Aug 13, 2026 | Filing ID: 097994
Read more
2026-08-14 17:57
New Form SCHEDULE 13G/A - Adagene Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001678057-26-000006 <b>Size:</b> 10 KB
Read more
2026-08-14 15:20
Director Grawunder Ulf 🟢 acquired 20.0K shares (1 derivative) of Adagene Inc. (ADAG) at $3.00 Transaction Date: Aug 13, 2026 | Filing ID: 000002
Read more
2026-08-12 11:30
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Read more
2026-06-08 07:23
New Form SCHEDULE 13D/A - Adagene Inc. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001104659-26-071145 <b>Size:</b> 12 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | Phase2 | Locally Advanced Colorectal Cancer | Recruiting | 2025-04-14 | 2027-12-31 | ClinicalTrials.gov |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast C… | Phase1 | Advanced Solid Tumor | Recruiting | 2023-06-12 | 2026-12-31 | ClinicalTrials.gov |
| NCT05614258 | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | Phase1 | Advanced/Metastatic Solid Tumors | Active_Not_Recruiting | 2023-02-13 | 2026-08-30 | ClinicalTrials.gov |
| NCT05405595 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic S… | Phase1 | Advanced/Metastatic Solid Tumors | Recruiting | 2022-06-15 | 2027-04-30 | ClinicalTrials.gov |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination … | Phase1 | HER2-negative Breast Cancer | Active_Not_Recruiting | 2022-05-19 | 2030-02-01 | ClinicalTrials.gov |
| NCT05277402 | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic S… | Phase1 | Advanced/Metastatic Solid Tumors | Completed | 2022-02-09 | 2022-12-01 | ClinicalTrials.gov |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | Phase1 | Metastatic Non Small Cell Lung Cancer | Unknown | 2021-11-12 | 2024-05-01 | ClinicalTrials.gov |
| NCT04645069 | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination… | Phase1 | Advanced/Metastatic Solid Tumors | Completed | 2021-03-15 | 2024-05-17 | ClinicalTrials.gov |
| NCT04524871 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Trea… | Phase1 | Advanced Liver Cancers | Recruiting | 2020-11-01 | 2027-09-30 | ClinicalTrials.gov |
| NCT04501276 | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-C… | Phase1 | Advanced/Metastatic Solid Tumors | Completed | 2020-09-23 | 2025-11-30 | ClinicalTrials.gov |
| NCT04111445 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | Phase1 | Solid Tumor | Terminated | 2019-08-29 | 2021-04-27 | ClinicalTrials.gov |
| NCT03802955 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lym… | Phase1 | Solid Tumor | Completed | 2018-12-20 | 2021-11-01 | ClinicalTrials.gov |
| NCT03707093 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or N… | Phase1 | Solid Tumors, Non-Hodgkin Lymphoma | Completed | 2018-09-17 | 2022-09-30 | ClinicalTrials.gov |
Total clinical trials: 13
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG116 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04111445 |
| ADG126-ADG106 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| ADG126-anti PD1 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| ADG126 Mono | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| ADG106 | Other | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | UNKNOWN | NCT05236608 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | UNKNOWN | NCT05236608 |
| ADG106 | Other | Phase PHASE1 | Solid Tumors, Non-Hodgkin Lymphoma | COMPLETED | NCT03707093 |
| ADG106 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03802955 |
| ADG106 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03802955 |
| ADG106 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03802955 |
| ADG116 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT05277402 |
| Pembrolizumab | Other | Phase PHASE2 | Locally Advanced Colorectal Cancer | RECRUITING | NCT06846268 |
| ADG126 | Other | Phase PHASE2 | Locally Advanced Colorectal Cancer | RECRUITING | NCT06846268 |
| Pembrolizumab & ADG106 (Phase II) | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05491083 |
| Pembrolizumab & ADG106 (Phase Ib) | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05491083 |
| Paclitaxel | Other | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| Cyclophosphamide | Other | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| Doxorubicin | Other | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| ADG106 | Other | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| ADG206 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05614258 |
| Standard of care (Fruquintinib) | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| Standard of Care (Trifluridine/Tipiracil-Bevacizumab) | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| Pembrolizumab (KEYTRUDA®) | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| ADG126 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| anti PD1 drug | Drug | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04501276 |
| ADG106 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04501276 |
| ADG116 | Other | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04501276 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 1200 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | Other | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Pembrolizumab | DRUG | Phase PHASE2 | Locally Advanced Colorectal Cancer | RECRUITING | NCT06846268 |
| ADG206 | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05614258 |
| Pembrolizumab & ADG106 (Phase II) | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05491083 |
| Pembrolizumab & ADG106 (Phase Ib) | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05491083 |
| Standard of care (Fruquintinib) | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| Standard of Care (Trifluridine/Tipiracil-Bevacizumab) | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| Pembrolizumab (KEYTRUDA®) | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | RECRUITING | NCT05405595 |
| Paclitaxel | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| Cyclophosphamide | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| Doxorubicin | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
| Nivolumab | DRUG | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | UNKNOWN | NCT05236608 |
| ADG126-ADG106 | BIOLOGICAL | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| ADG126-anti PD1 | BIOLOGICAL | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| ADG126 Mono | BIOLOGICAL | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04645069 |
| IO-108 1200 mg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| NKT2152 | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| IO-108 1800 mg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| ADG126 | DRUG | Phase PHASE2 | Locally Advanced Colorectal Cancer | RECRUITING | NCT06846268 |
| Tobemstomig 1200 mg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 600 mg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 10 mg/kg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tobemstomig 2100 mg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| TPST-1120 | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tocilizumab | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Tiragolumab | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Bevacizumab 15 mg/kg | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| Atezolizumab | DRUG | Phase PHASE1 | Advanced Liver Cancers | RECRUITING | NCT04524871 |
| anti PD1 drug | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT04501276 |
| ADG116 | DRUG | Phase PHASE1 | Advanced/Metastatic Solid Tumors | COMPLETED | NCT05277402 |
| ADG106 | DRUG | Phase PHASE1 | HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05275777 |
Total products: 304